COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors

Alessandro Leonetti; Francesco Facchinetti; Teresa Zielli; Elena Brianti; Marcello Tiseo

doi:10.1016/j.ejca.2020.04.004

Journal articles

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors

Alessandro Leonetti ^{1, 2} Francesco Facchinetti ^{3, 4, *} Teresa Zielli ¹ Elena Brianti ⁴ Marcello Tiseo ^{1, 2}

* Corresponding author

1 University Hospital of Parma [Parme, Italie]

2 University of Parma

3 PMNCO - Prédicteurs moléculaires et nouvelles cibles en oncologie

4 Fidenza Hospital [Parme, Italie]

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Life Sciences [q-bio] / Human health and pathology / Pulmonology and respiratory tract

Life Sciences [q-bio] / Microbiology and Parasitology / Virology

Life Sciences [q-bio] / Human health and pathology / Emerging diseases

Complete list of metadatas

Cited literature [8 references] Display Hide Download

https://www.hal.inserm.fr/inserm-02565846
Contributor : Myriam Bodescot <>
Submitted on : Wednesday, May 6, 2020 - 4:54:59 PM
Last modification on : Saturday, October 3, 2020 - 4:16:17 AM

PIIS0959804920301933.pdf

Publication funded by an institution

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors

File

Identifiers

Collections

Citation

Export

Metrics

127

211

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors

File

Identifiers

Collections

Citation

Export

Share

Metrics

127

211